Novel cancer immunotherapy antibody compositions
By developing antigenic peptides or antibodies that can bind to human PD-L1, the interaction between PD-L1 and PD1 is blocked, T cells are activated, the problem of intratumoral immunosuppression is solved, and the therapeutic effect on a variety of cancers is enhanced.
CN116410320BActive Publication Date: 2026-06-191GLOBE BIOMEDICAL CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- 1GLOBE BIOMEDICAL CO LTD
- Filing Date
- 2019-08-20
- Publication Date
- 2026-06-19
AI Technical Summary
Technical Problem
Existing cancer treatments are unable to effectively block the immunosuppressive environment within tumors, especially through the ectopic expression of inhibitory immune checkpoint ligands such as PD-L1, which leads to the suppression of T cells and their inability to effectively kill tumor cells.
Method used
An antigen-binding peptide or antibody has been developed that can bind to human PD-L1, inhibit its interaction with PD1, and kill tumor cells through ADCC and CDC mechanisms, and can be combined with other immunotherapeutic agents for the treatment of tumors.
Benefits of technology
By blocking the interaction between PD-L1 and PD1, T cells are activated, enhancing the anti-tumor immune response and improving the treatment effect on various cancers.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN116410320B_ABST
Abstract
The present invention provides novel compositions and methods related to or derived from anti-PD-L1 antibodies having ADCC and / or CDC activity. More specifically, the present invention discloses fully human antibodies that bind PD-L1, PD-L1 binding antibody fragments and derivatives, and PD-L1 binding polypeptides comprising these fragments.
Need to check novelty before this filing date? Find Prior Art